Prevalence and Clinical Implications of COVID-19 Myocarditis

[1]  aguda y crónica,et al.  Comments on the 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. , 2022, Revista espanola de cardiologia.

[2]  C. Lavalle,et al.  Flecainide in Ventricular Arrhythmias: From Old Myths to New Perspectives , 2021, Journal of clinical medicine.

[3]  P. Palange,et al.  Cardiac involvement in consecutive unselected hospitalized COVID-19 population: In-hospital evaluation and one-year follow-up , 2021, International Journal of Cardiology.

[4]  M. Capobianchi,et al.  Virus-Negative Necrotizing Coronary Vasculitis with Aneurysm Formation in Human SARS-CoV-2 Infection , 2021, Infectious disease reports.

[5]  D. Carretta,et al.  Cardiac Involvement in COVID-19 Patients: A Contemporary Review , 2021, Infectious disease reports.

[6]  C. Esopenko,et al.  Prevalence of Clinical and Subclinical Myocarditis in Competitive Athletes With Recent SARS-CoV-2 Infection , 2021, JAMA cardiology.

[7]  C. Lavalle,et al.  Flecainide How and When: A Practical Guide in Supraventricular Arrhythmias , 2021, Journal of clinical medicine.

[8]  G. Finocchiaro,et al.  COVID-19 and myocarditis: a systematic review and overview of current challenges , 2021, Heart Failure Reviews.

[9]  J. Burkhardt,et al.  Catheter Ablation of Life-Threatening Ventricular Arrhythmias in Athletes , 2021, Medicina.

[10]  Dhanunjaya R. Lakkireddy,et al.  Catheter Ablation of Ventricular Tachycardia in Ischemic Cardiomyopathy: Impact of Concomitant Amiodarone Therapy on Short and Long-Term Clinical Outcomes. , 2021, Heart rhythm.

[11]  Angelo B. Biviano,et al.  Worldwide Survey of COVID-19–Associated Arrhythmias , 2021, Circulation. Arrhythmia and electrophysiology.

[12]  D. Mele,et al.  Myocarditis in COVID-19 patients: current problems , 2021, Internal and Emergency Medicine.

[13]  C. Granger,et al.  Effect of Discontinuing vs Continuing Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers on Days Alive and Out of the Hospital in Patients Admitted With COVID-19: A Randomized Clinical Trial. , 2021, JAMA.

[14]  R. Virmani,et al.  Pathological Evidence for SARS-CoV-2 as a Cause of Myocarditis , 2021, Journal of the American College of Cardiology.

[15]  Christopher M. Horvat,et al.  Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19 , 2021, medRxiv.

[16]  M. Cunningham,et al.  Multisystem Inflammatory Syndrome in Children (MIS-C), a Post-viral Myocarditis and Systemic Vasculitis—A Critical Review of Its Pathogenesis and Treatment , 2020, Frontiers in Pediatrics.

[17]  A. Roy,et al.  Cardiac Magnetic Resonance Imaging in Coronavirus Disease 2019 (COVID-19): A Systematic Review of Cardiac Magnetic Resonance Imaging Findings in 199 Patients. , 2020, Journal of thoracic imaging.

[18]  M. T. Medina,et al.  Repurposed Antiviral Drugs for Covid-19 — Interim WHO Solidarity Trial Results , 2020, The New England Journal of Medicine.

[19]  G. Francis,et al.  Update on COVID-19 Myocarditis , 2020, Medicina.

[20]  Mario J. Garcia,et al.  Evidence of systemic endothelial injury and microthrombosis in hospitalized COVID-19 patients at different stages of the disease , 2020, Journal of Thrombosis and Thrombolysis.

[21]  C. Agrati,et al.  Virus-Negative Myopericarditis in Human Coronavirus Infection , 2020, Circulation. Heart failure.

[22]  Mario J. Garcia,et al.  T-wave inversion as a manifestation of COVID-19 infection: a case series , 2020, Journal of Interventional Cardiac Electrophysiology.

[23]  Jennifer L. Bell,et al.  Effect of Hydroxychloroquine in Hospitalized Patients with COVID-19 , 2020, The New England Journal of Medicine.

[24]  S. Rizzo,et al.  Pathological features of COVID-19-associated myocardial injury: a multicentre cardiovascular pathology study , 2020, European heart journal.

[25]  S. Antinori,et al.  Arrhythmic safety of hydroxychloroquine in COVID-19 patients from different clinical settings , 2020, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[26]  F. Fedele,et al.  Management of cardiac implantable electronic device follow‐up in COVID‐19 pandemic: Lessons learned during Italian lockdown , 2020, Journal of cardiovascular electrophysiology.

[27]  K. Sawalha,et al.  Systematic Review of COVID-19 Related Myocarditis: Insights on Management and Outcome , 2020, Cardiovascular Revascularization Medicine.

[28]  Yvonne Darlington,et al.  Observation , 2020, Qualitative research in practice Stories from the field.

[29]  Eike Nagel,et al.  Outcomes of Cardiovascular Magnetic Resonance Imaging in Patients Recently Recovered From Coronavirus Disease 2019 (COVID-19) , 2020, JAMA cardiology.

[30]  P. Kirchhof,et al.  Association of Cardiac Infection With SARS-CoV-2 in Confirmed COVID-19 Autopsy Cases. , 2020, JAMA cardiology.

[31]  J. Q. Brown,et al.  Unexpected Features of Cardiac Pathology in COVID-19 Infection. , 2020, Circulation.

[32]  Thomas Jaki,et al.  Dexamethasone in Hospitalized Patients with Covid-19 — Preliminary Report , 2020, The New England journal of medicine.

[33]  A. Natale,et al.  Non‐pulmonary vein triggers in nonparoxysmal atrial fibrillation: Implications of pathophysiology for catheter ablation , 2020, Journal of cardiovascular electrophysiology.

[34]  G. Ligabue,et al.  Cardiac Magnetic Resonance Characterization of Myocarditis-Like Acute Cardiac Syndrome in COVID-19 , 2020, JACC: Cardiovascular Imaging.

[35]  B. Abella,et al.  COVID-19 and cardiac arrhythmias , 2020, Heart Rhythm.

[36]  B. Bayrakci,et al.  Fulminant COVID-19-related myocarditis in an infant , 2020, European heart journal.

[37]  C. Hamm,et al.  Detection of viral SARS‐CoV‐2 genomes and histopathological changes in endomyocardial biopsies , 2020, ESC heart failure.

[38]  G. Sayer,et al.  Approach to Acute Cardiovascular Complications in COVID-19 Infection. , 2020, Circulation. Heart failure.

[39]  Kipp W. Johnson,et al.  Prevalence and Impact of Myocardial Injury in Patients Hospitalized With COVID-19 Infection , 2020, Journal of the American College of Cardiology.

[40]  Amit N. Patel,et al.  Retraction: Cardiovascular Disease, Drug Therapy, and Mortality in Covid-19. N Engl J Med. DOI: 10.1056/NEJMoa2007621. , 2020, The New England journal of medicine.

[41]  Y. Arbel,et al.  Spectrum of Cardiac Manifestations in COVID-19 , 2020, Circulation.

[42]  R. V. Vander Heide,et al.  Pulmonary and cardiac pathology in African American patients with COVID-19: an autopsy series from New Orleans , 2020, The Lancet Respiratory Medicine.

[43]  C. S. Kow,et al.  Glucocorticoid versus immunoglobulin in the treatment of COVID-19-associated fulminant myocarditis , 2020, Infection.

[44]  L. Cooper,et al.  Recognizing COVID-19–related myocarditis: The possible pathophysiology and proposed guideline for diagnosis and management , 2020, Heart Rhythm.

[45]  A. Selva-O'Callaghan,et al.  Immunomodulatory therapy for the management of severe COVID-19. Beyond the anti-viral therapy: A comprehensive review , 2020, Autoimmunity Reviews.

[46]  P. Zimetbaum,et al.  Risk of QT Interval Prolongation Associated With Use of Hydroxychloroquine With or Without Concomitant Azithromycin Among Hospitalized Patients Testing Positive for Coronavirus Disease 2019 (COVID-19). , 2020, JAMA cardiology.

[47]  Eun Ji Kim,et al.  Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area. , 2020, JAMA.

[48]  Jin Young Kim,et al.  COVID-19-related myocarditis in a 21-year-old female patient , 2020, European heart journal.

[49]  Lei Liu,et al.  First case of COVID-19 complicated with fulminant myocarditis: a case report and insights , 2020, Infection.

[50]  C. Basso,et al.  Acute myocarditis presenting as a reverse Tako-Tsubo syndrome in a patient with SARS-CoV-2 respiratory infection , 2020, European heart journal.

[51]  E. Coomes,et al.  Interleukin‐6 in Covid‐19: A systematic review and meta‐analysis , 2020, medRxiv.

[52]  E. Behr,et al.  SARS-CoV-2, COVID-19, and inherited arrhythmia syndromes , 2020, Heart Rhythm.

[53]  Dhanunjaya R. Lakkireddy,et al.  Guidance for cardiac electrophysiology during the COVID-19 pandemic from the Heart Rhythm Society COVID-19 Task Force; Electrophysiology Section of the American College of Cardiology; and the Electrocardiography and Arrhythmias Committee of the Council on Clinical Cardiology, American Heart Associat , 2020, Heart Rhythm.

[54]  Jing Yuan,et al.  Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma. , 2020, JAMA.

[55]  Mohammad Madjid,et al.  Potential Effects of Coronaviruses on the Cardiovascular System: A Review. , 2020, JAMA cardiology.

[56]  Roberto Maroldi,et al.  Cardiac Involvement in a Patient With Coronavirus Disease 2019 (COVID-19). , 2020, JAMA cardiology.

[57]  Tao Guo,et al.  Cardiovascular Implications of Fatal Outcomes of Patients With Coronavirus Disease 2019 (COVID-19) , 2020, JAMA cardiology.

[58]  W. Gong,et al.  Association of Cardiac Injury With Mortality in Hospitalized Patients With COVID-19 in Wuhan, China. , 2020, JAMA cardiology.

[59]  Allan Schwartz,et al.  COVID-19 and Cardiovascular Disease , 2020, Circulation.

[60]  Xin Zhou,et al.  Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China , 2020, The Journal of Emergency Medicine.

[61]  P. Mehta,et al.  COVID-19: consider cytokine storm syndromes and immunosuppression , 2020, The Lancet.

[62]  J. Burkhardt,et al.  Simple Electrocardiogaphic Criteria for Rapid Identification of Wide QRS Complex Tachycardia: the new Limb Lead Algorithm. , 2020, Heart rhythm.

[63]  J. Baillie,et al.  Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury , 2020, The Lancet.

[64]  Wei Liu,et al.  Clinical characteristics of novel coronavirus cases in tertiary hospitals in Hubei Province , 2020, Chinese medical journal.

[65]  Ting Yu,et al.  Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study , 2020, The Lancet.

[66]  G. Gao,et al.  A Novel Coronavirus from Patients with Pneumonia in China, 2019 , 2020, The New England journal of medicine.

[67]  L. Cooper,et al.  Recognition and Initial Management of Fulminant Myocarditis , 2020, Circulation.

[68]  F. Marchlinski,et al.  Variant of ventricular outflow tract ventricular arrhythmias requiring ablation from multiple sites: Intramural origin. , 2019, Heart rhythm.

[69]  Matthias Gutberlet,et al.  Cardiovascular Magnetic Resonance in Nonischemic Myocardial Inflammation: Expert Recommendations. , 2018, Journal of the American College of Cardiology.

[70]  R. Blankstein,et al.  Prognostic Value of Cardiac Magnetic Resonance Tissue Characterization in Risk Stratifying Patients With Suspected Myocarditis. , 2017, Journal of the American College of Cardiology.

[71]  M. Russo,et al.  Increased oxidative stress contributes to cardiomyocyte dysfunction and death in patients with Fabry disease cardiomyopathy. , 2015, Human pathology.

[72]  A. Frustaci,et al.  Immunosuppressive therapy in myocarditis. , 2014, Circulation journal : official journal of the Japanese Circulation Society.

[73]  Lisa E. Gralinski,et al.  Molecular pathology of emerging coronavirus infections , 2014, The Journal of pathology.

[74]  S. Grupp,et al.  Current concepts in the diagnosis and management of cytokine release syndrome. , 2014, Blood.

[75]  M. Russo,et al.  Inhibition of cardiomyocyte lysosomal activity in hydroxychloroquine cardiomyopathy. , 2012, International journal of cardiology.

[76]  K. Klingel,et al.  Long-term follow-up of biopsy-proven viral myocarditis: predictors of mortality and incomplete recovery. , 2012, Journal of the American College of Cardiology.

[77]  Jan Gunnar Fjeld,et al.  A novel clinical method for quantification of regional left ventricular pressure–strain loop area: a non-invasive index of myocardial work , 2012, European heart journal.

[78]  F. Romeo,et al.  Predictive value of fragmented QRS in primary prevention implantable cardioverter defibrillator recipients with left ventricular dysfunction , 2011, Journal of cardiovascular medicine.

[79]  Elizabeth R. Duffy,et al.  Altered Desmosomal Proteins in Granulomatous Myocarditis and Potential Pathogenic Links to Arrhythmogenic Right Ventricular Cardiomyopathy , 2011, Circulation. Arrhythmia and electrophysiology.

[80]  Carl J Pepine,et al.  Endothelium as a Predictor of Adverse Outcomes , 2010, Clinical cardiology.

[81]  C. Lavalle,et al.  Atrial tachyarrhythmias and cardiac resynchronisation therapy: clinical and therapeutic implications , 2010, Heart.

[82]  C. Schneider,et al.  ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: application of natriuretic peptides. , 2008, European heart journal.

[83]  B. McManus,et al.  Molecular biology and pathogenesis of viral myocarditis. , 2008, Annual review of pathology.

[84]  M. Jessup,et al.  The role of endomyocardial biopsy in the management of cardiovascular disease: a scientific statement from the American Heart Association, the American College of Cardiology, and the European Society of Cardiology. , 2007, Circulation.

[85]  A. Angelini,et al.  A prospective study of biopsy-proven myocarditis: prognostic relevance of clinical and aetiopathogenetic features at diagnosis. , 2007, European heart journal.

[86]  Global, regional, and national incidence, prevalence, and YLDs for 301 acute and chronic diseases and injuries for 188 countries, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013 , 2015 .

[87]  Matthias Gutberlet,et al.  Cardiovascular Magnetic Resonance in Myocarditis: A JACC White Paper , 2009 .